UNIGE document Scientific Article
previous document  unige:1203  next document
add to browser collection

Rapamycin in islet transplantation: friend or foe?

Secchi, Antonio
Published in Transplant International. 2009, vol. 22, no. 2, p. 153-61
Abstract The Edmonton protocol was undoubtedly a major step forward in the history of islet transplantation. Its immunosuppression regimen was largely based on the mTOR inhibitor rapamycin (sirolimus), which remains the most frequently used immunosuppressive drug in clinical islet transplant protocols. As time reveals the somewhat disappointing long-term results achieved with the Edmonton protocol, a number of publications have appeared addressing the potential beneficial or deleterious role of rapamycin on islet cell engraftment, function survival and regeneration, as well as on its side-effects in human subjects. This paper reviews the sometimes contradictory evidence on the impact of rapamycin in islet transplantation.
Keywords Diabetes Mellitus/drug therapy/immunologyHumansImmune Tolerance/drug effectsImmunosuppressive Agents/adverse effects/pharmacologyInsulin-Secreting Cells/drug effectsIslets of Langerhans Transplantation/immunologySirolimus/adverse effects/pharmacology
PMID: 18713146
Full text
Article (Accepted version) (177 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group La transplantation d'îlots de Langerhans (623)
(ISO format)
BERNEY, Thierry, SECCHI, Antonio. Rapamycin in islet transplantation: friend or foe?. In: Transplant International, 2009, vol. 22, n° 2, p. 153-61. doi: 10.1111/j.1432-2277.2008.00743.x https://archive-ouverte.unige.ch/unige:1203

461 hits



Deposited on : 2009-03-20

Export document
Format :
Citation style :